Packaging Safety Seed-To-Sale Treatment 
MMJ Recs
MARCH 16, 2024
This burgeoning industry encompasses a wide range of activities, including cultivation, processing, distribution, and retail sales of medical cannabis products. The establishment of cultivation, processing, and dispensary facilities creates a diverse array of employment opportunities, spanning from agricultural roles to retail positions.
Cannabis Law Report
JULY 30, 2021
The FDA is currently in an ongoing process evaluating the science and safety of CBD and hemp derivatives in order to determine potential regulatory pathways for hemp. While unlikely to pass in this Congress, the momentous legislation gives us a roadmap for how the U.S. Industry stakeholders have until September 1, 2021 to provide feedback.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 17, 2022
Mycotoxins are contaminants that licensees are required to screen for to uphold public health, safety, and welfare. ACK Natural, LLC recently disclosed that there are quarantined product packages for which verifiable test results cannot be produced because they were fully sold. PRESS RELEASE.
Cannabis Law Report
SEPTEMBER 10, 2022
A lack of federal regulation allowed for largely unregulated sales of intoxicating, artificially derived cannabinoids online and even to minors. In response, Oregon’s marijuana regulatory agency, the OLCC, promulgated administrative rules to ban the sale of most artificially-derived cannabinoids in Oregon. [2].
Cannabis Law Report
AUGUST 19, 2019
19 August 2019. Authors – Carolyn E. Pepper and Jess Parry. Recently, three British MPs went to Canada on a fact-finding cross-party trip to consider the effects of a more relaxed regulatory environment in respect of cannabis. What substances are at issue? Cannabinoids are the chemical substances found in cannabis.
Cannabis Law Report
OCTOBER 6, 2021
Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.). Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).
The Joint Blog
MAY 19, 2020
But the pressure is on, because even though it’s still early days, the cannabis industry is set to grow significantly, and sales are projected to hit over $20 billion in the next few years. The truth is that cannabis is, for many people, an extremely important treatment that’s set to become mainstream. Over half the states in the U.S.
Expert insights. Personalized for you.
105 
Let's personalize your content